Document Detail

A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors.
MedLine Citation:
PMID:  23143778     Owner:  NLM     Status:  Publisher    
Background Several cancer therapies can prolong cardiac repolarization. This study assessed the potential of eribulin to affect cardiac repolarization in patients with advanced solid tumors. Methods In this Phase I, open-label, single-arm study, patients received eribulin mesylate (1.4 mg/m(2); Days 1 and 8 of a 21-day cycle). The primary objective was to assess the effect of eribulin on the QTcF pre- and post-infusion; QTcF and QTcNi were compared for ability to remove heart-rate dependence of the QT interval. Relationship between concentration of eribulin and ΔQTc was explored using linear mixed-effects analysis. Secondary objectives explored pharmacokinetics, safety, and tolerability. Results Twenty-six patients were enrolled. QTcNi was more effective than QTcF in correcting for heart-rate dependency of the QT interval. On Day 1, mean ΔQTcNi were ~0 at all timepoints. An apparent time-dependent increase in ΔQTc was observed: on Day 8, changes from baseline were larger and more variable, without clear relation to plasma levels of eribulin. Day 8 predose ΔQTcNi was 5 ms, post-infusion mean values ranged from 2 to 9 ms (largest mean ΔQTcNi at 6 h). No new or unexpected toxicities were reported. Conclusion Eribulin demonstrated an acceptable safety profile and a minor prolongation of QTc not expected to be of clinical concern in oncology patients.
Thierry Lesimple; Julien Edeline; Timothy J Carrothers; Frédérique Cvitkovic; Borje Darpo; Jean-Pierre Delord; Hervé Léna; Nicolas Penel; Geoff J Edwards; Kenneth Law; Jantien Wanders; Allan Kristensen; Larisa Reyderman
Related Documents :
12511778 - Ultra-early hemostatic therapy for intracerebral hemorrhage.
2120988 - Treatment of arteriovenous malformations of the brain with combined embolization and st...
2689398 - The role of radiation therapy in the management of childhood craniopharyngioma.
15665258 - A prospective multicenter study to evaluate the feasibility and safety of aggressive an...
22984818 - Prospective, multicentre, randomized controlled trial of bladder filling prior to trial...
23851988 - Aortic valve replacement in geriatric patients with small aortic roots: are sutureless ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-11
Journal Detail:
Title:  Investigational new drugs     Volume:  -     ISSN:  1573-0646     ISO Abbreviation:  Invest New Drugs     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-12     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8309330     Medline TA:  Invest New Drugs     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Clinical Research Unit, Medical Oncology Department, Comprehensive Cancer Center Eugène Marquis, CS 44229, 35042, Rennes Cedex, France,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Targeting a regulatory element in human thymidylate synthase mRNA.
Next Document:  Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines.